Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Replicel Life Sciences Inc (REPCF)

Replicel Life Sciences Inc (REPCF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.65
Trade REPCF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0398 +7.54%
on 02/28/24
0.0496 -13.71%
on 02/27/24
+0.0059 (+15.99%)
since 02/15/24
3-Month
0.0340 +25.88%
on 02/09/24
0.0735 -41.77%
on 12/18/23
-0.0313 (-42.24%)
since 12/14/23
52-Week
0.0257 +66.54%
on 12/05/23
0.1860 -76.99%
on 06/09/23
-0.0609 (-58.73%)
since 03/15/23

Most Recent Stories

More News
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing

This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing

Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Announces Material Patent Milestones

New DermaPreciseâ„¢ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc....

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Closed Final Tranche of Strategic Investment Commitment

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Terminates License Agreement with Shiseido

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing

Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,...

RP : 88.72 (+0.08%)
REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2)...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line

Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Announces Dermal Injector Update

Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE / October...

RP : 88.72 (+0.08%)
REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor

Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC / ACCESSWIRE...

RP.VN : 0.055 (unch)
REPCF : 0.0428 (+4.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Replicel Life Sciences Inc was incorporated under the Ontario Business Corporations Act on April 24, 1967. The Company is a clinical stage biopharmaceutical company engaged in developing autologous cell therapies that treat functional cellular deficits. RepliCel Tendon-01 (RCT-01) is a cell therapy for...

See More

Key Turning Points

3rd Resistance Point 0.0428
2nd Resistance Point 0.0428
1st Resistance Point 0.0428
Last Price 0.0428
1st Support Level 0.0428
2nd Support Level 0.0428
3rd Support Level 0.0428

See More

52-Week High 0.1860
Fibonacci 61.8% 0.1248
Fibonacci 50% 0.1059
Fibonacci 38.2% 0.0869
Last Price 0.0428
52-Week Low 0.0257

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar